Your browser doesn't support javascript.
loading
Synchronous detection of multiple myeloma and acute myeloid leukemia: A diagnostic and therapeutic challenge.
Maral, Senem; Albayrak, Murat; Sahin, Osman; Ozturk, Hacer Berna Afacan; Han, Unsal; Falay, Mesude.
Afiliación
  • Maral S; Department of Hematology, Ankara Diskapi Research and Training Hospital, Ankara, Turkey.
  • Albayrak M; Department of Hematology, Ankara Diskapi Research and Training Hospital, Ankara, Turkey.
  • Sahin O; Department of Hematology, Ankara Diskapi Research and Training Hospital, Ankara, Turkey.
  • Ozturk HBA; Department of Hematology, Ankara Diskapi Research and Training Hospital, Ankara, Turkey.
  • Han U; Department of Pathology and Cytology, Ankara Diskapi Research and Training Hospital, Ankara, Turkey.
  • Falay M; Department of Hematology, Ankara Numune Research and Training Hospital, Ankara, Turkey.
J Oncol Pharm Pract ; 27(2): 464-469, 2021 Mar.
Article en En | MEDLINE | ID: mdl-33620259
ABSTRACT

INTRODUCTION:

Synchronous detection of multiple myeloma and acute myeloid leukemia in a single patient is a rare coincidence. Treatment of these patients is still unclear, mostly based on acute myeloid leukemia strategies combined with bortezomib. CASE REPORT A 72-year-old male with no medical history was investigated for pancytopenia. On medical examination, he was complicated with a wide and severe skin infection on arm. On examination of bone marrow aspirate, 25% myeloblasts infiltration and additional 10% plasma cells were seen. Acute myeloid leukemia was diagnosed and plasma cell proliferation was attributed to reactive plasmacytosis due to skin infection. However, flowcytometric studies and immunohistochemical examination revealed two different cell populations with 30-40% atypical plasma cells and >20% myeloblasts. Serum M-protein detected by serum electrophoresis test and immunofixation test revealed a monoclonal IgG lambda band. He was diagnosed with concurrent acute myeloid leukemia and multiple myeloma without history of chemotherapy.Management and

outcome:

The patient was initially treated with bortezomib and dexamethasone for the myeloma. Subsequently, azacitidine was administered subcutaneously for the acute myeloid leukemia treatment. The tru-cut biopsy of the lesion on his arm revealed suppurative inflammatory findings and no malign cells detected. Antibiotherapy was started according to susceptibility. He expired after three months of survival.

DISCUSSION:

The synchronous occurrence of these two different clonal hematological malignancies is rare in hematology practice. Patient-based prospective studies and case series are needed to guide diagnosis and treatment strategies. Furthermore, this report highlights the importance of ruling out reactive plasmacytosis in patients with hematological malignancy who developed severe infections.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Observational_studies / Qualitative_research / Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2021 Tipo del documento: Article País de afiliación: Turquía

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Observational_studies / Qualitative_research / Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2021 Tipo del documento: Article País de afiliación: Turquía